Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 2 Interventional Results available

An Extension Study of 12 mg Proellex® (Telapristone Acetate) Administered Orally in the Treatment of Premenopausal Women With Confirmed Symptomatic Uterine Fibroids

ClinicalTrials.gov ID: NCT02811159

Public ClinicalTrials.gov record NCT02811159. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 6:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open-Label Extension Study of 12 mg Proellex® (Telapristone Acetate) Administered Orally in the Treatment of Premenopausal Women With Confirmed Symptomatic Uterine Fibroids

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

To determine the safety of extended treatment with Proellex® in women who have successfully completed either study ZPV-201 \[NCT02323646\] or ZPU-203 \[NCT02301897\] and meet eligibility criteria.

Study identification

NCT ID
NCT02811159
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Lead sponsor
Repros Therapeutics Inc.
Industry
Enrollment
20 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years to 47 Years
Sex
Female
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 26, 2016 (Actual)
Primary completion
May 4, 2017 (Actual)
Completion
May 4, 2017 (Actual)
Last update posted
Jun 27, 2019

2016 – 2017

United States locations

U.S. sites
8
U.S. states
6
U.S. cities
7
Facility City State ZIP Site status
KO Clinical Research, LLC Fort Lauderdale Florida 33316 —
Atlanta Women's Research Institute, Inc. Atlanta Georgia 30342 —
WR-Mount Vernon Clinical Research, LLC Sandy Springs Georgia 30328 —
Southern Clinical Research Associates, LLC Metairie Louisiana 70001 —
The Jackson Clinic, PA Jackson Tennessee 38305 —
Advances in Health Houston Texas 77030 —
The Women's Hospital of Texas Clinical Research Center Houston Texas 77054 —
Clinical Research Partners, LLC Richmond Virginia 23235 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02811159, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 27, 2019 · Synced Oct 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT02811159 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →